恒瑞医药：注射用SHR-A2102联合阿得贝利单抗联合SHR-1802开展临床试验获批

Core Viewpoint - 恒瑞医药's subsidiaries have received approval from the National Medical Products Administration for clinical trials of three new drug candidates, indicating progress in their oncology pipeline [1][2][3] Group 1: Drug Candidates - SHR-A2102 is a targeted antibody-drug conjugate (ADC) developed by the company, targeting Nectin-4, with a total R&D investment of approximately 224.84 million yuan. The global sales of a similar product, Enfortumab vedotin, are projected to be around 1.949 billion USD in 2024 [1] - SHR-1802 is a humanized monoclonal antibody that activates and promotes anti-tumor T cell responses, with no similar products approved in China and a total R&D investment of about 62.09 million yuan [2] - 阿得贝利单抗注射液 is a humanized anti-PD-L1 monoclonal antibody that has been approved for use in combination with carboplatin and etoposide for first-line treatment of extensive-stage small cell lung cancer. The total R&D investment for this product is approximately 939.08 million yuan, and similar products in the market have a combined global sales forecast of about 9.648 billion USD in 2024 [3]